The U.S. Food and Drug Administration (FDA) mandates adequate enrollment of women in post-approval studies (PAS) of medical devices to ensure that any sex differences in device safety and effectiveness are not overlooked. A group of authors from the FDA report the results of a study evaluating the participation of women and analysis of sex differences in PAS in Journal of Women’s Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.
Women may respond differently to medical devices due to factors such as genetics, body size, hormones, or other intrinsic sex-specific or extrinsic societal or environmental factors. They may face greater or lesser risk of adverse events or derive more or less benefit. “Based on these findings, FDA implemented new procedures to ensure participation by sex is evaluated in PAS reviews,” state the authors in their article “Enrollment and Monitoring of Women in Post-Approval Studies for Medical Devices Mandated by the Food and Drug Administration.”
“It is critically important that we have adequate participation of women in clinical trials, and that we analyze sex differences in study outcomes and adverse events,” says Editor-in-Chief Susan G. Kornstein, MD, Executive Director of the Virginia Commonwealth University Institute for Women’s Health, Richmond, VA, and President of the Academy of Women’s Health.
Enrollment and Monitoring of Women in Post-Approval Studies for Medical Devices Mandated by the Food and Drug Administration, Authors: Ellen Pinnow, MS, Naomi Herz,BS, Nilsa Loyo-Berrios, PhD, and Michelle Tarver, MD, PhD, Journal of Women’s Health – doi:10.1089/jwh.2013.4343